Global Gastrointestinal Stromal Tumors Market – OverviewOne of the most common form of sarcoma is gastrointestinal stromal tumors (GIST) involving the gastrointestinal tract.
Gastrointestinal stromal tumors can occur anyplace within the GI tract but is most often found in the stomach i.e.
Every year approximately 11 to 20 million people worldwide are diagnosed with GIST.research report on “Gastrointestinal Stromal Tumors Market Research Report – Forecast to 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.Bayer AG (Germany) Novartis AG (Switzerland), Immunicum AB (Sweden), F. Hoffmann-La Roche Ltd.(Switzerland), AB SCIENCES (FRANCE), Arog Pharmaceuticals, Inc. (U.S), Boston Biomedical, Inc. (U.S) are some of the prominent players at the forefront of competition in the Global Gastrointestinal Stromal Tumors Market and are profiled in MRFR Analysis.The global gastrointestinal stromal tumors market segments on the basis of the indication, diagnosis, treatment, and end-user.Global Gastrointestinal Stromal Tumors Market – Regional AnalysisGlobal gastrointestinal stromal tumors market is segmented on the basis of geographies or regions which mainly includes North America, Europe, Asia Pacific, and Middle East & Africa.
According to Centers for Disease Control and Preventation, every year in the U.S. about 22,000 men & 9,000 women get liver cancer, and more than 16,000 men & 8,000 women die from the same disease.
The percentage of Americans who develop liver cancer has been rising from past few decades.
More over the presence of major manufacturers in the region and the development for the products has been influencing the growth of the market.Europe holds the second largest share of the global gastrointestinal stromal tumors market.